Research & Development

Tonix announces collaboration to develop precision medicine techniques for Covid-19 vaccines and therapeutics

Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

US university says common FDA-approved drug may effectively neutralise SARS-CoV-2 virus

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.

Merck opens largest M Lab Collaboration Centre in Shanghai

Merck, a leading science and technology company, opened its M Lab Collaboration Centre in Shanghai, the company's largest of nine centers worldwide.

Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients

Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Pfizer commits $100m to support development of new antibiotics

Major drugmaker Pfizer has committed $100m to the new Antimicrobial Resistance (AMR) Action Fund, which will support the development of new antibiotics due to increasing antibiotic-resistant infections.

Oxygen Sensor InPro 6860iHD

Reliable Oxygen Measurements Continuous dissolved oxygen (DO) measurement is critical during fermentation and cell culture.

Vor Biopharma closes $110m Series B financing

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.

Goldfinch Bio raises $100m to develop therapies for kidney diseases

Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.